Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells

Oncology Research

Volumn 9, Issue 4, 1997, Pages 155-166

  Kremenetskaya, Olga S ^a   Logacheva, Nataliya P ^a   Baryshnikov, Anatoly Y ^a   Chumakov, Peter M ^a   Kopnin, Boris P ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Apoptosis; Cell differentiation; Chronic myelogenous leukemia; P53 mutations

Indexed keywords

LEUKOCYTE ANTIGEN; PROTEIN P53;

ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL SURVIVAL; CULTURE MEDIUM; ERYTHROLEUKEMIA; GENETIC TRANSFECTION; GENETICS; HUMAN; MOUSE; PATHOLOGY; PHENOTYPE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIGENS, CD; APOPTOSIS; CELL DIFFERENTIATION; CELL SURVIVAL; CULTURE MEDIA; GENES, P53; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MICE; PHENOTYPE; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030626833     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Hartwell, L. H.; Kastan, M. B. Cell cycle control and cancer. Science 266:1821-1828; 1994.
2. Haffener, R.; Oren, M. Biochemical properties and biological effects of p53. Curr. Opin. Genet. Dev. 5:84-90; 1995.
3. Chernova, O. B.; Chernov, M. V.; Agarwal, M. L.; Taylor, W. R.; Stark G. R. The role of p53 in regulating genomic stability when DNA and RNA synthesis are inhibited. Trends Biochem. 20:431-434; 1995.
4. Cox, L. S.; Lane, D. P. Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in responce to DNA damage. Bioessays 17:501-508; 1995.
5. Jacks, T.; Weinberg, R. A. Cell-cycle control and its watchman. Nature 381:643-644; 1996.
6. El Deiry, W. S.; Tokino, T.; Velculescu, P. M.; Levy, D. B.; Parsons, B.; Trent, J. M.; Lin, D.; Mercer, W. E.; Kinzler, K. W.; Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825; 1993.
7. Dulic, V.; Kaufmann, W. K.; Wilson, S. J.; Tlsty, T. D.; Lees, M.; Harper, W.; Elledge, S. J.; Reed, S. I. p53dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced Gl arrest. Cell 76:1013-1023; 1994.
8. El Deiry, W. S.; Harper, J. W.; O'Connor, P. M.; Velculescu, P. M.; Canman, C. E.; Jackman, J.; Pietenpol, J. A.; Burrel, M.; Hill, D. E.; Whang, J.; Kinzler, K. W.; Vogelstein, B. Waf1/cip1 is induced in p53-mediated Gl arrest and apoptosis. Science 262:1644-1645; 1994.
9. Zhan, Q.; Lord, K. A.; Alamo, J. J.; Hollander, M. C.; Carrier, F.; Ron, D.; Kohn, W. W.; Hoffman, B.; Lieberman, D. A.; Fornace, A. J. J. The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Mol. Cell. Biol. 14:23612371; 1994.
10. Miyashita, T.; Krajewsky, S.; Krajewska, M.; Wang, H. G.; Lin, H. K.; Lieberman, D. A.; Hoffman, B.; Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805; 1994.
11. Miyashita, T.; Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293299; 1995.
12. Owen-Schaub, L. B.; Zhang, W.; Cusack, J. C.; Angelo, L. S.; Santee, S. M.; Fujiwara, T.; Roth, J. A.; Deisseroth, A. B.; Zhang, W. W.; Kruzel, E. Wild-type p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol. 15:3032-3040; 1995.
13. Seto, E.; Usheva, A.; Zambetti, G. P.; Momand, J.; Horikoshi, N.; Weinmann, R.; Levine, A. J.; Shenk, T. Wild-type p53 binds to the TATA binding protein and represses transcription. Proc. Natl. Acad. Sei. USA 89:12028-12032; 1992.
14. Ragimov, N.; Krauskopf, A.; Navot, N.; Rotter, V.; Oren, M.; Aloni, Y. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA-motif. Oncogene 8: 1183-1193; 1993.
15. Horikoshi, N.; Usheva, A.; Chen, J.; Levine, A. J.; Weinmann, R.; Shenk, T. Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol. Cell. Biol. 15:227-234; 1995.
16. Miyashita, T.; Harigai, M.; Hanada, M.; Reed, J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 54:3131-3135; 1994.
17. Shaulsky, G.; Goldfinger, N.; Peled, A.; Rotter, V. Involvement of wild-type p53 in pre-B-cell differentiation in vitro. Proc. Natl. Acad. Sei. USA 88:8982-8986; 1991.
18. Ronen, D.; Schwartz, D.; Teitz, Y.; Goldfinger, N.; Rotter, V. Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels. Cell Growth Differ. 7:21-30; 1996.
19. Feinstein, E.; Gale, R. P.; Reed, J.; Canaani, E. Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene 7:1853-1857; 1992.
20. Ehinger, M.; Nilsson, E.; Persson, A. M.; Olsson, I.; Gullberg, U. Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562. Cell Growth Differ. 6:9-17; 1995.
21. Greenblatt, M. S.; Bennet, W. P.; Hollstein, M.; Harris, C. C. Mutations in the p53 tumor suppressor gene: Clues to cancer ethiology and molecular pathogenesis. Cancer Res. 54: 4855-4878;1994.
22. Levine, A. J.; Wu, M. C.; Chang, A.; Silver, A.; Attiyeh, E. F.; Lin, J.; Epstein, C. B. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles and a "gain of function" phenotype. Ann. NY Acad. Sei. 768:111-128; 1995.
23. Hollstein, M.; Rice, K.; Greenblatt, M. S.; Sousssi, T.; Fuchs, R.; Sortie, T.; Hovig, E.; Smith Sorensen, B.; Montesano, R.; Harris, C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22:35513555;1994.
24. Lozzio, C. B.; Lozzio, R. B. Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 45:321-334; 1975.
25. Anderson, L. C.; Nillson, K.; Gahmberg, C. G. K562-a human erythroleukemic cell line. Int. J. Cancer 23:143-147; 1979.
26. Lubbert, M.; Miller, C. W.; Crawford, L.; Koeffler, H. P. p53 in chronic myelogenous leukemia. J. Exp. Med. 167:873886; 1988.
27. Law, J. C.; Rilke, M. K.; Galowich, J. C.; Leder, G. M.; Ferrell, R. E. Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk. Res. 17:10451050;1993.
28. Kopnin, B. P.; Stromskaya, T. P.; Kondratov, R. V.; Ossovskaya, V. S.; Pugacheva, E. N.; Rybalkina, E. Y.; Khokhlova, O. A.; Chumakov, P. M. Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts. Oncol. Res. 7:299-306; 1995.
29. Michalovitz, D.; Halevy, O.; Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperaturesensitive mutant p53. Cell 62:671-680; 1990.
30. Yonish Rouach, E.; Resnitzky, D.; Lote, M. J.; Sachs, L.; Kimchi, A.; Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347; 1991.
31. Turkina, A. G.; Baryshnikov A. Yu.; Sedykhina, N. P.; Folomeskhina, S. V.; Sokolova, M. A.; Choroshco, N. D.; Stavrovskaya, A.A. Studies of P-glycoprotein in chronic myelogenous leukaemia patients: Expression, activity, and correlations with CD34 antigen. Br. J. Heamatol. 92:88-96; 1996.
32. Baryshnikov, A. Y.; Polosukhina, E. R.; Zabotina, T. N.; Burova, O. S.; Chinareva, I. V.; Golubtsova, N. V.; Mitina, T. A.; Koroleva, A. M.; Kuznetsov, S. V.; Palkina, T. N. Monoclonal antibody to antigen CD24. Biotechnology (Mosk.) 12:12-14; 1995.
33. Baryshnikov, A. Y.; Frolova, E. A.; Leneva, N. V.; Palkina, T. N.; Kadagidze, Z. G.; Guttefanges, S.; Dostot, E.; Schmid, M.; Korvaya, N.; Mansur, I.; Bonsussan A.; Boumsell, L. Monoclonal antibody ICO-92 to transferrin receptor (antigen CD71). Proc. Russian Acad. Sei. 38:524-528; 1993.
34. Botsenovsky, V. A.; Zabotina, T. N.; Kulevich, E. E.; Sedyakhina, N. P.; Baryshnikov, A. Y.; Chistyakova, O. B. Monoclonal antibody ICO-GM1 to antigen CDllb. Herald Cancer Res. Centre (Mosk.) No 2:8-11; 1995.
35. Tupitsin, N.; Mechetner, E.; Baryshnikov, A.; Drozdova, T.; Frenkel, M.; levleva, E.; Kiselev, A.; Perilov, A.; Peterson, I.; Probatova, A.; Rozinova, E.; Tonevitsky, A.; Volkova, M. Two different antierythroid monoclonal antibodies in immunodiagnostics of human leukemias: A comparative study. Int. J. Cancer 44:589-592; 1989.
36. Schlossman, S. F.; Boumsell, L.; Gilks, W.; Harlan, J. M.; Kishimoto, T.; Morimoto, C.; Ritz, J.; Shan, S.; Silverstein, R.; Springer, T.; Tedder, T. F.; Todd, R. F., eds. Lecocyte typing V white cell differentiation antigens. Oxford-New York: Oxford University Press; 1995.
37. Whitehead, R. H.; Macrae, F. A.; St. John, D. J. B.; Ma, J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J. Natl. Cancer Inst. 74:759-765; 1885.
38. Johnson, P.; Gray, D.; Mowat, M.; Benchimol, S. Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. Mol. Cell. Biol. 11:1-11; 1991.
39. Akira, A.; Toga, T.; Kishimoto, T. Interleukin-6 in biology and medicine. Adv. Immunol. 54:1-17; 1993.
40. Blandino, G.; Scardigli, R.; Rizzo, M. G.; Crescenci, M.; Soddu, S.; Sacchi, A. Wild-type p53 modulates apoptosis of normal IL-3 deprived hematopoietic cells. Oncogene 10:731737; 1995.
41. Canman, C. E.; Gilmer, T. M.; Coutts, S. B.; Kastan, M. B. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev. 9:600-611; 1995.
42. Lin, Y.; Benchimol, S. Cytokines inhibit p53-mediated apoptosis but not p53-mediated Gl arrest. Mol. Cell. Biol. 15: 6045-6054; 1995.
43. Lotem, J.; Sachs, L. Interpheron-gamma inhibits apoptosis induced by wild-type p53, cytotoxic anti-cancer agents, and viability factor deprivation in myeloid cells. Leukemia 9:685692; 1995.
44. Chumakov, A. M.; Miller, C. W.; Chen, D. L.; Koeffler, H. P. Analysis of p53 transactivation through high-affinity binding sites. Oncogene 8:3005-3011; 1995.
45. Zhang, W.; Funk, W. D.; Wright, W. E.; Shay, J. W.; Deisseroth, A. B. Novel DNA-binding of p53 mutants and their role in transcriptional activation. Oncogene 8:2555-2559; 1993.
46. Park, D. J.; Nakamura, H.; Chumakov, A. M.; Said, J. N.; Miller, C. W.; Chen, D. L.; Koeffler, H. P. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 9:1899-1906; 1994.
47. Niewolik, D.; Vojetesek, B.; Kovarik, J. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 10:881-890; 1995.
48. Muller, B. B.; Paulsen, D.; Deppert, W. Specific binding of MAR/SAR DNA-elements by mutant p53. Oncogene 12: 1941-1952; 1996.
49. Chin, K. V.; Ueda, K.; Pastan, I.; Gottesman, M. M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459-462; 1992.
50. Dittmer, D.; Pâti, S.; Zambetti, G.; Chu, S.; Teresky, A. K.; Moore, M.; Finlay, C.; Levine, A. J. Gain of function mutations in p53. Nature Genet. 4:42-46; 1993.
51. Deb, S.; Jackson, C. T.; Subler, M. A.; Martin, D. W. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J. Virol. 66:6164-6170; 1992.
52. Chumakov, P. M.; Pugacheva, E. N.; Ossovskaya, V. S.; Kondratov, R. V.; Kuznetsov, N. V.; Ivanov, A. V.; Prassolov, V. S.; Mazo, I. A.; Gudkov, A. V.; Kopnin, B. P. Functions of the p53 involved in control of malignant transformation. In: Cancer and the cell cycle. ISREC-AACR symposium. Lausanne: ISREC Press; 1996:A-35.
53. Zhang, W.; Grasso, L.; McLain, C. D.; Gambel, A. M.; Cha, Y.; Travali, S.; Deisseroth, A. B.; Mercer, W. E. p53independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res. 55:668-674; 1995.
54. Ishizaki, Y.; Cheng, L.; Mudge, A. W.; Raff, M. C. Programmed cell death by default in embryonic cells, fibroblasts, and cancer cells. Mol. Biol. Cell. 6:1443-1458; 1995.